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To assess the feasibility and clinical eﬃcacy of local ﬁeld potentials (LFPs)–based adaptive deep
brain stimulation (aDBS) in patients with advanced Parkinson disease (PD) during daily
activities in an open-label, nonblinded study.
Methods
We monitored neurophysiologic and clinical ﬂuctuations during 2 perioperative experimental
sessions lasting for up to 8 hours. On the ﬁrst day, the patient took his/her daily medication,
while on the second, he/she additionally underwent subthalamic nucleus aDBS driven by LFPs
beta band power.
Results
The beta band power correlated in both experimental sessions with the patient’s clinical state
(Pearson correlation coeﬃcient r = 0.506, p < 0.001, and r = 0.477, p < 0.001). aDBS after LFP
changes was eﬀective (30% improvement without medication [3-way analysis of variance,
interaction day × medication p = 0.036; 30.5 ± 3.4 vs 22.2 ± 3.3, p = 0.003]), safe, and well
tolerated in patients performing regular daily activities and taking additional dopaminergic
medication. aDBS was able to decrease DBS amplitude during motor “on” states compared to
“oﬀ” states (paired t test p = 0.046), and this automatic adjustment of STN-DBS prevented
dyskinesias.
Conclusions
Themain ﬁndings of our study are that aDBS is technically feasible in everyday life and provides
a safe, well-tolerated, and eﬀective treatment method for the management of clinical
ﬂuctuations.
Classification of evidence
This study provides Class IV evidence that for patients with advanced PD, aDBS is safe, well
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Optimizing deep brain stimulation (DBS) therapy for patients
with Parkinson disease (PD) now seems feasible thanks to the
successful results of preliminary studies on closed-loop,
adaptive DBS (aDBS) strategies aimed at providing the best
stimulation parameters according to the patient’s clinical
state.1–5 aDBS is thought to overcome classic DBS therapy
limitations, including stimulation-induced side eﬀects in the
long term such as gait and speech impairment and the pres-
ence of motor ﬂuctuations not well controlled.6–8
To adapt stimulation parameters, aDBS uses the synchronous
presynaptic and postsynaptic activity of local neuronal pop-
ulations (local ﬁeld potentials [LFPs]) recorded through the
same implanted electrodes delivering stimulation. The power
of the beta band oscillation (11–35 Hz), which is modulated
by levodopa administration, movement execution and prep-
aration, motor planning, and DBS,6–8 is considered the most
promising biomarker for aDBS.
Two main adaptation strategies have been tested in humans.
The ﬁrst one is based on an on-oﬀ approach that activates
DBS only when the LFP beta power exceeds a personalized
threshold,1,2 and the second approach linearly modulates the
stimulation voltage according to the changes in the LFP beta
power, adapting moment-by-moment DBS parameters to the
patient’s state.3,4 In both cases, aDBS proved to be more
eﬀective than conventional DBS in improving motor scores,1
in controlling levodopa-induced dyskinesias,3,4 and in re-
ducing speech-related side eﬀects.5
Despite the positive results, available data were obtained in
short experimental sessions, up to 2 hours.3,4
As a preliminary step for developing an implantable device, in
this work, we aimed to investigate in a long time window in an
open-label, nonblinded study whether aDBS is able to follow
and control clinical ﬂuctuations using beta band power
changes and is well tolerated by and safe for patients.
Methods
We enrolled 13 rigid-akinetic patients with advanced PD who
underwent surgery for subthalamic nucleus DBS electrode
implantation in the Neurosurgery Unit at Fondazione IRCCS
Ca’Granda Ospedale Maggiore Policlinico in Milan from
March 2016 to January 2017 without experiencing any sur-
gical complication. The study was approved by the in-
stitutional review board and conformed with the Declaration
of Helsinki, and all patients provided written informed
consent to the experimental procedures. Patients were
implanted bilaterally but studied unilaterally. The choice of
the side is detailed in appendix e-1, http://links.lww.com/
WNL/A238.
The experimental sessions took place after DBS surgery be-
fore the leads were connected to the subcutaneous pulse
generator.
Before the experimental session started, a calibration session
was performed to verify the presence of a signiﬁcant beta peak
in at least 1 side, to establish the best side for recording LFPs
and testing aDBS, and to establish eﬀective stimulation
parameters (appendix e-1, http://links.lww.com/WNL/
A238). Because, according to the literature,9 we expected that
the beta peak was not detectable in all patients and because
the current aDBS algorithm is based on beta band modu-
lations, those not showing a beta peak were excluded from the
study.
The experimental protocol (ﬁgure 1A) included two 8-hour
sessions (1 per day) conducted with a portable aDBS pro-
totype device9: day 1, stimulation “oﬀ” and LFP recordings
“on”; and day 2, stimulation “on” (aDBS) and LFP record-
ings “on.”
After 12 hours of medication withdrawal, each session
started with a baseline assessment (medication “oﬀ,”
stimulation “oﬀ ”). The patient took his/her ﬁrst morning
medication afterward and was then assessed when his/her
medication was eﬀective (medication “on,” peak dose
≈45–60 minutes after medication intake) and then when
the medication ended its eﬀects (medication “oﬀ,” end dose
60–90 minutes after the peak dose). The same procedure
was repeated throughout the 8 hours (ﬁgure 1A).
According to the personal response timing, each patient
took 2 or 3 medications. Hence, to allow comparisons, we
considered the clinical assessments related to the ﬁrst 2
administrations. On day 2, DBS was switched “on” at the
beginning of the experimental session, immediately after
the baseline assessment. The clinical assessments on day 2
followed the same schema as on day 1, according to levo-
dopa response (peak dose, end dose).
For the clinical assessment, we collected the Uniﬁed
Parkinson’s Disease Rating Scale, part III, motor part
(UPDRS III), the Uniﬁed Dyskinesias Rating Scale
(UDysRS), parts 3 and 4, and the adverse events (AEs)
experienced by the patient (appendix e-1, http://links.lww.
com/WNL/A238 for AE classiﬁcation).
Glossary
aDBS = adaptive deep brain stimulation; AE = adverse event; ANOVA = analysis of variance; DBS = deep brain stimulation;
LFP = local ﬁeld potential; PD = Parkinson disease; UDysRS = Uniﬁed Dyskinesias Rating Scale; UPDRS III = Uniﬁed
Parkinson’s Disease Rating Scale, part III.
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To assess the aDBS device function throughout the whole
8-hour session, we collected the beta band power and, on day
2, the stimulation amplitude. We correlated the clinical as-
sessment with the beta power corresponding to the time at
which the UPDRS III was assessed (±10 minutes). We also
collected the patient’s physical activity using a wearable
commercial bracelet equipped with a 3-axis accelerometer. A
dedicated application was developed to acquire and store data
and to provide a clinical diary (sleep, rest, walk, talk, eat,
other) to be ﬁlled in by the patient every 30 minutes.
We used data on day 1 to verify the ability of beta band power
to act as a biomarker of patient’s state, and more speciﬁcally,
we tested whether the beta power was modulated by levodopa
using nonsupraliminar levodopa doses (paired t test beta
power “oﬀ” vs beta power “on,” p < 0.05), the beta power
Figure 1 Experimental protocol and aDBS functioning
(A) Top timeline shows the activities recorded during the 8 hours (10 AM–6 PM) for a representative patient. Middle plot represents the activity index (i.e.,
a custom index based on accelerometer data in the band of 0.5–4 Hz representing the amount of motor activity) corresponding to each activity, and the
bottom trace is beta power percentage change from baseline throughout the 8 hours. Bottom arrows show the times in which the patient was assessed
(baseline, peak dose 1, end dose 1, peak dose 2, end dose 2) and received levodopa. (B) Beta power changes from baseline in day 1 (top trace) and day 2
(bottom trace) of a representative patient (patient 4). The x-axis represents time (hours) and y-axis represents percent beta power change frombaseline. Gray
rectangles highlight beta power during clinical assessments (baseline, peak dose 1, end dose 1, peak dose 2, end dose 2). (C) Average beta power changes
from baseline in day 1 (top trace) and day 2 (bottom trace). Only the time windows of ±10 minutes around clinical assessments were represented to allow
averaging among patients. The x-axis represents time (hours) and y-axis represents percent beta power change frombaseline. Gray rectangles highlight beta
power during clinical assessments (baseline, peak dose 1, end dose 1, peak dose 2, end dose 2). aDBS = adaptive deep brain stimulation; AU = arbitrary units;
UPDRS = Unified Parkinson’s Disease Rating Scale.
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correlated to the patient’s clinical state as measured by the
UPDRS III (Pearson correlation coeﬃcient, p < 0.05), and the
beta power correlated with the speciﬁc physical activities as
measured by the wearable bracelet (Pearson correlation co-
eﬃcient, p < 0.05).
aDBS eﬃcacy was assessed by a comparison of clinical data
(UPDRS III and UDysRS) collected on day 1 vs 2 (3-way
analysis of variance [ANOVA] with the factors day [2 levels,
day 1 and day 2], condition [2 levels, medication “on” and
medication “oﬀ”], and administration [2 levels, administra-
tion 1 and administration 2]). aDBS safety was veriﬁed by the
occurrence and intensity of AEs related to stimulation. Data
here are reported as mean ± standard error.
Results
We screened 13 patients (table 1). Of them, only 1 patient
(patient 5) did not show a signiﬁcant beta peak, and we lost the
entire day 1 recording of patient 6 because of battery discharge.
Hence, we analyzed 11 patients. Experimental details are
reported in table e-1, http://links.lww.com/WNL/A237.
In day 1, we found that the beta power responded to levodopa
administration, as expected, with an average decrease of 18.0 ±
0.03% in peak dose compared to a 8.3 ± 0.03% in end dose
(p = 0.009) with respect to baseline (medication “oﬀ,”
stimulation “oﬀ,” after 12 hours of levodopa withdrawal). In
addition, the beta power was conﬁrmed to correlate with the
patient’s clinical state as measured by the UPDRS III (Pearson
correlation coeﬃcient = 0.477, p < 0.001) and was speciﬁcally
modulated during walking with respect to talking and relaxing
(beta power change from baseline during: walking −14.0 ±
4.212%, talking −11.2 ± 2.724%, relaxing −8.8 ± 2.418%, 1-
way ANOVA p < 0.0001).
On day 2 (ﬁgure 2), we observed that aDBS was eﬀective in
reducing UPDRS III motor scores by almost 30% when the
patients were “oﬀ” medication, whereas no improvement was
observed in day 1 when the patients did not receive aDBS
(baseline vs medication “oﬀ”: day 1, 32.6 ± 2.8 vs 29.4 ± 3.9;
day 2, 30.5 ± 3.4 vs 22.2 ± 3.3; 3-way ANOVA interaction day
× levodopa p = 0.036; post hoc test p = 0.003). When the
patients were “on” levodopa, the cumulative eﬀect of aDBS
and levodopa provided a 45% improvement in the UPDRS III
motor scores that was comparable to that elicited by levodopa
alone on day 1 (baseline vs medication “on”: day 1, 32.6 ± 2.8
vs 17.9 ± 2.0; day 2, 30.5 ± 3.4 vs 15.5 ± 2.3; post hoc test p =
0.4). The cumulative eﬀect of levodopa and aDBS did not
elicit dyskinesias (medication “oﬀ” vs medication “on”: day 1,
3.4 ± 1.0 vs 5.8 ± 1.7; day 2, 3.5 ± 0.9 vs 4.4 ± 1.5; 3-way
ANOVA interaction day × levodopa p = 0.51). In fact, as
expected, the amount of stimulation voltage delivered when
the patient was on levodopa peak was signiﬁcantly lower
than that delivered when the patient was in the end peak
Table 1 Patients’ preoperative clinical details
















1 1 M 59 10 6 R 208 25 13
2 2 M 62 9 6 R 685.55 41 18
3 3 M 67 12 5 R 1,494 25 10
4 4 M 50 8 5 R 1,055 32 16
5 5 M 47 11 2.5 R 1,080 19 10
6 6 M 58 7 2 R 1,856.66 37 11
7 7 F 65 14 4 L 652 22 8
8 8 M 70 12 2 L 872 13 3
9 9 F 47 7 2 L 1,436.1 24 8
10 10 M 54 13 4.5 L 785 24 8
11 11 M 59 14 12 L 665 30 10
12 12 F 58 11 5 L 1,250 39 16
13 13 F 70 13 7 L 208 25 12
Abbreviations: LEDD = levodopa equivalent daily dose; UPDRS = Unified Parkinson’s Disease Rating Scale.
a Preoperative response to levodopa refers to UPDRS III score assessed by a neurologist at the time of indication for DBS surgery (≈6months before surgery).
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(normalized stimulation voltage as a percent of the maximum
voltage in table e-1, http://links.lww.com/WNL/A237,
medication “oﬀ” vs medication “on”: 0.67 ± 0.23 vs 0.38 ±
0.37, paired t test p = 0.046). As a further veriﬁcation of the
aDBS functioning, we found that the beta power was con-
ﬁrmed to correlate with the patient’s clinical state as measured
by the UPDRS III (Pearson correlation coeﬃcient = 0.506,
p < 0.001) even in day 2. Finally, no AEs speciﬁcally related to
aDBS or complaints regarding either the experimental pro-
cedure or the device/stimulation were reported.
Discussion
In our 8-hour experiment, our aDBS device provided a stim-
ulation output that was always calibrated to the beta rhythm
and to the patient’s state.
To the best of our knowledge, this is the longest experiment with
aDBS. Previous experiments with aDBS from our group and
other laboratories showed aDBS eﬀectiveness in shorter time
windows.1–5 Our observations showed that changing DBS volt-
age linearly with beta rhythm provides constant beneﬁt for hours
of unrestricted patient activity and in conjunction with normal
levodopa assumption. Conversely, in previous experiments, to
understand whether aDBS was able to control stimulation side
eﬀects better than conventional DBS, patients were administered
a supraliminal dose of levodopa, able to induce dyskinesias, es-
pecially if summed to DBS.3,4
Despite these new insights provided by the current experi-
ment, this study has some limitations. First, aDBS was de-
livered with an external prototype immediately after the
surgery for DBS electrode placement, in the so-called acute
experimental setting. In this time window, several adaptation
processes at the level of the tissue-electrode interface occur,
and the presence of edema and the lesional eﬀect due to
electrode insertion limit the possibility to mimic the more
stable chronic phase. In addition, unilateral aDBS was applied,
and the study was conducted in an open-label, unblinded
fashion. Finally, the analysis of daily of life activities (e.g.,
talking, relaxing, sleeping) was based on a self-reporting diary
Figure 2 aDBS efficacy on day 2
(A) Graph represents average UPDRS III values on day 1 (green line) and day 2 (light gray line) at baseline, at end dose/medication “off,” and at peak dose/
medication “on.” Error bars are SEMs. UPDRS III values at end dose/medication “off ” on day 1 were significantly different from those on day 2 and from those
on peak dose/medication “on” on the sameday 1. (B) Graph represents averageUDysRS, part III and IV values on day 1 (green line) and on day 2 (light gray line)
at baseline, at end dose/medication “off,” and at peak dose/medication “on.” Error bars are SEMs. No significant differences were detected among conditions.
(C) Details of theUPDRS III values on day 1 (green line) and onday 2 (light gray line) at baseline, at enddose/medication “off,” and at peak dose/medication “on”
in the 2 sessions throughout the whole 8-hour experiment. On day 1, only values at peak dose/medication “on”were different from baseline values, whereas
on day 2, the difference was significant at all time points after aDBS was turned on. (D) Histogram represents the average voltage change in the peak dose/
medication “on” condition (green) and in the end dose/medication “off ” (light gray) during day 2. Error bars are SEMs. aDBS = adaptive deep brain stimulation;
HSD = highest significant difference; UPDRS = Unified Parkinson’s Disease Rating Scale; UDysRS = Unified Dyskinesias Rating Scale.
Neurology.org/N Neurology | Volume 90, Number 11 | March 13, 2018 e975
and on the data from a single accelerometer placed on the
patient’s wrist in 30-minute time windows. This provided an
indication of the predominance of a certain activity during this
time frame, and it cannot track the probable co-occurrence of
diﬀerent activities. To account for this intrinsic inaccuracy, the
beta power was studied in average during the time frame. This
approach, however, provided evidence of an average correla-
tion between the beta power and the patient’s activity that
should be better studied with more quantitative approaches
based on multiple sensors.
Although still obtained in an acute experimental setting a few
days after DBS surgery, our results show that beta band–based
aDBS can induce stable control of PD-related motor dis-
turbances by adapting stimulation parameters according to
the patient’s state. Overall, this ﬁnding is a step forward in the
development of the new generation of implantable aDBS
devices for treating PD.
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Is local ﬁeld potential (LFP)-based adaptive deep brain stimu-
lation (aDBS) administered during daily activities feasible and
eﬀective for patients with advanced Parkinson disease (PD)?
Summary answer
LFP-based aDBS is a feasible, safe, well-tolerated, and eﬀec-
tive way to manage these patients’ clinical ﬂuctuations.
What is known and what this paper adds
LFP-based aDBS may provide improvements over classic
DBS techniques, but available evidence comes from experi-
mental sessions that only lasted up to 2 hours. This study
provides Class IV evidence for the feasibility and eﬃcacy of
LFP-based aDBS over longer sessions, up to 8 hours.
Participants and setting
This study examined 13 patients with rigid-akinetic advanced
PD at a Department of Clinical Neurology and Neurosurgery
in Milan, Italy between March 2016 and January 2017.
Design, size, and duration
The participants underwent surgical insertion of DBS electrodes
into the subthalamic nucleus and then underwent two 8-hour
experimental sessions over consecutive days. LFP recordings
were conducted during both sessions, but aDBS was activated
only in the second session. The patients took their prescribed
medications on both days. Clinical assessments weremade based
on the Uniﬁed PD Rating Scale (UPDRS), the Uniﬁed Dyski-
nesias Rating Scale, and adverse events.
Primary outcomes
The primary outcomes were correlations during long lasting
recordings (up to 8 hours) between beta band power and
UPDRS scores and comparisons between UPDRS scores on
days 1 and 2.
Main results and the role of chance
Beta band power correlated with UPDRS scores on days 1
(Pearson’s r = 0.477; p < 0.001) and 2 (Pearson’s r = 0.506; p
< 0.001). Activating aDBS achieved a nearly 30% reduction in
day 2 UPDRS motor scores when patients were “oﬀ” levo-
dopa that was not observed when comparing analogous
timepoints on day 1 (p = 0.003). When patients were “on”
levodopa, the combined eﬀect of aDBS and levodopa on day 2
was a ;45% reduction in UPDRS motor scores comparable
to that observed for levodopa alone on day 1 (p = 0.4). No
aDBS-related adverse events, including dyskinesia, were
reported.
Bias, confounding, and other reasons
for caution
This was an unblinded open-label study. The experiments
were conducted immediately after implantation surgeries, so
adaptation processes had not yet occurred.
Generalizability to other populations
The aDBS algorithm here validated is speciﬁc for PD-STN
target, but the feasibility and safety of the aDBS approach is
potentially generalizable to other DBS indications.
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